What JYNARQUE Does

JYNARQUE® (tolvaptan) may help change the course of your disease

Kidney function

JYNARQUE is the first and only FDA-approved treatment proven to slow kidney function decline in adults who are at risk for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

JYNARQUE slows the decline in kidney function

Data from a 1-year clinical study of patients with chronic kidney disease (CKD) stages 2 to 4

Kidney Function Over 1 Year with JYNARQUE, Graph 1 yea r star t Stage 3b Stage 3a Stage 4 mL/min/1.73 m 2 30 45 Speed of decline slowed by 35% Kidney function (average eGFR) over time* Difference JYNARQUE made JYNARQUE Placebo
Kidney Function Over 1 Year with JYNARQUE, Graph Difference JYNARQUE made Placebo JYNARQUE 1 yea r star t Stage 3b Stage 3a Stage 4 mL/min/1.73 m 2 3 0 4 5 Speed of decline slowed by 35% . Kidney function (average eGFR) over time*

*Kidney function or estimated glomerular filtration rate (eGFR) is measured in units of mL/min/1.73 m2.

Data from a 3-year clinical study of patients with CKD stages 1 to 3

Kidney Function Over 3 Years with JYNARQUE, Graph Difference JYNARQUE made JYNARQUE Placebo 1 year start 2 years 3 years Stage 2 Stage 1 Stage 3a mL/min/1.73 m 2 60 90 Kidney function (average eGFR) over time* Speed of decline slowed by 26%
Kidney Function Over 3 Years with JYNARQUE, Graph Speed of decline slowed by 26% . 1 year start 2 years 3 years Stage 2 Stage 1 Stage 3a mL/min/1.73 m 2 60 90 Kidney function (average eGFR) over time* Difference JYNARQUE made Placebo JYNARQUE

*Kidney function or eGFR is measured in units of mL/min/1.73 m2.

JYNARQUE is proven to slow kidney function decline in adults who are at risk for rapidly progressing ADPKD.

Kidney pain

Patients taking JYNARQUE had less kidney pain

36% Less Kidney Pain Events with JYNARQUE
36% Less Kidney Pain Events with JYNARQUE

In a clinical trial of ADPKD patients with CKD stages 1 to 3, patients taking JYNARQUE had

36% fewer pain events

requiring medication or other treatment than those taking placebo.

 

Treatment was defined as:

  • Prescribed leave
  • Surgery
  • Radiologic treatment

Disease stages

JYNARQUE works at different stages of the disease

JYNARQUE is for adults at risk of having rapidly progressing ADPKD. With JYNARQUE, you may be able to slow the progression of your disease—at any stage of CKD.

JYNARQUE works across CKD stages 1 to 4

2 3 4 1 STAGES OF CKD Study 1 Study 2
4 3 2 1 Study 1 Study 2 STAGES OF CKD

JYNARQUE is not for everyone. Ask your doctor to see if JYNARQUE is right for you.

JYNARQUE is a long-term treatment that has been studied in many patients

  • JYNARQUE is a proven treatment that has been studied in over 3000 people with ADPKD, and prescribed to over 5500 people
  • JYNARQUE may change the course of your disease by slowing kidney function decline as it works over a period of years. As you take JYNARQUE, remember that it is a long-term treatment and it may take time to see a difference

Start slowing your disease progression with JYNARQUE. Talk to your doctor to see if JYNARQUE is the right treatment option for you.

Please read IMPORTANT SAFETY INFORMATION for JYNARQUE, including BOXED WARNING and MEDICATION GUIDE, below.


How JYNARQUE works

How does JYNARQUE work?

JYNARQUE works by blocking a hormone that can cause cysts to grow in people with ADPKD.

CYST JYNARQUE works by preventing vasopressin from binding in the kidneys, making it harder for cysts to grow J JYNARQUE Receptor Vasopressin is a hormone that maintains the volume of water in the fluid space surrounding the cells. People with ADPKD have too much vasopressin, causing kidney cysts to grow. V V V V V V V V V V V
V Vasopressin is a hormone that maintains the volume of water in the fluid space surrounding the cells. People with ADPKD have too much vasopressin, causing kidney cysts to grow. CYST J JYNARQUE Receptor V V V V V V V V V V JYNARQUE works by preventing vasopressin from binding in the kidneys, making it harder for cysts to grow

For illustrative purposes only.

Video